PATH enters the week with the stock down nearly 7% and multiple analysts cutting price targets on the same day — a post-earnings hangover playing out in real time after a punishing September 3 print.
The most notable move landed Tuesday: Truist Securities slashed its target from $17 to $14, and UBS dropped its from $19 to $15, both maintaining neutral-to-hold stances. RBC Capital similarly trimmed to $15. The directional message from the Street is consistent — no one is panicking into a downgrade, but conviction is eroding. Needham stands apart, holding a Buy with a $22 target. Citigroup initiated at Buy with a $23 target on September 8, just before the stock's sharpest leg down. The consensus mean target is now $16.32, roughly 23% above Tuesday's close of $13.25, but that gap reflects stale optimism more than a genuine bull setup. The analyst recommendation differential factor ranks in the 94th percentile — an unusually wide dispersion between bulls and bears that reflects real disagreement about the path forward.
The bear case has fresh ammunition. UiPath's most recent earnings on September 3 produced a -15.6% next-day drop and a -22.9% five-day slide — one of the sharpest single-event drawdowns in the stock's recent history. The bear case centres on multiple compression across the software sector, a declining dollar-based net revenue retention rate of 107%, and questions about margin expansion alongside the WorkFusion acquisition. The bull case leans on revenue growth of roughly 14% year-on-year, ARR climbing to $1.85 billion, and a growing cohort of $100K-plus customers. Valuation has cheapened — EV/EBITDA has contracted by 0.84 turns over the past month, the P/B multiple is down 0.5 turns, and the P/E has fallen more than four points over the same stretch. At a trailing P/E of roughly 15x and an EV/EBITDA near 10x, the stock is no longer expensive by historical software standards, but the growth-to-valuation trade-off is far from obvious.
Short positioning tells a nuanced story. At 22.75% of free float, short interest is genuinely elevated — this is not background noise. It dipped roughly 11% from mid-August levels (when it ran above 120 million shares) and has been roughly flat on the week, which means shorts who survived the September 3 move have largely stayed put rather than covering into the weakness. The ORTEX short score is 62.4, edging up modestly through the week, with the short score rank in the 11th percentile — meaning most of the universe is more heavily shorted, but PATH is still firmly in high-short territory. What limits the squeeze setup is availability: at 184.6% of short interest, there are nearly two shares available to borrow for every one already shorted. Borrowing costs are cheap at 0.44% and have eased around 5% on the week and 23% over the past month. The borrow market is comfortable, which means there is no mechanical pressure on existing shorts to exit.
Options positioning is calm relative to the backdrop. The put/call ratio at 0.64 is almost exactly in line with its 20-day average of 0.63, with a z-score of just 0.14 — no unusual demand for downside protection despite the stock's rough week. That is a mild divergence from what the price action might suggest: options traders are not scrambling to hedge, even as the stock revisits multi-month lows. The 52-week PCR range runs from 0.22 to 0.70, and the current reading is comfortably in the upper half without reaching extremes.
On the ownership side, the founder CEO Daniel Dines remains the largest holder at 17.5% of shares, though his position edged lower in the most recent 13G/A filing in February (down from 19.9% to 19.2%). Tetragon has been building — adding roughly 10 million shares across two tranches through mid-year. Insider activity in recent weeks has been almost exclusively 10b5-1 plan sales by the CPO/CTO and COO, totalling around $2 million in disclosed value. These are pre-arranged and carry limited signal, but the 90-day net insider position shows roughly $26.9 million net sold — a meaningful number that sits in contrast to Tetragon's institutional accumulation.
The next earnings event is December 2, giving the market roughly ten weeks to reassess whether the September print was a one-quarter stumble or something more structural — and whether target cuts still in the mid-to-high teens can hold up against a stock trading at $13.25.
See the live data behind this article on ORTEX.
Open PATH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
